Figure 2.

Immunogenicity of gH/gL nanoparticles

(A) C57BL/6 mice (n = 10 mice for gH/gL monomer and 4-, 7-, and 24-mer, and n = 12 for gH/gL 60-mer) were immunized with monomeric gH/gL or multimeric gH/gL nanoparticles at weeks 0, 4, and 12. Blood was collected 2 weeks after each immunization.

(B) Endpoint plasma binding titers to gH/gL were measured by ELISA. Each dot represents the reciprocal endpoint titer for an individual mouse measured in duplicate. Box and whisker plots represent the minimum, 25^th percentile, median, 75^th percentile, and maximum values.

(C and D) The ability of plasma from individual mice to neutralize EBV infection of epithelial cells (C) or B cells (D). Each dot represents the reciprocal half-maximal inhibitory dilution (ID₅₀) titer of an individual mouse. Plasma that did not achieve 50% neutralization at the lowest dilution tested (1:20) was assigned a value of 10. Box and whisker plots represent the minimum, 25^th percentile, median, 75^th percentile, and maximum values. Significant differences in B–D were determined using Mann-Whitney tests with Holm-adjusted p values (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).

See also Figures S1 and S2.